Core Viewpoint - Concerns raised by HHS Secretary Robert F. Kennedy Jr. regarding the efficacy of Novavax's protein-based COVID-19 vaccine have led to a significant decline in the company's stock price, which fell by 19.6% on April 10 [1][2]. Company Summary - Novavax's COVID-19 vaccine has been authorized for emergency use in the U.S. since 2022 and is also approved in multiple markets including Australia, Canada, Europe, India, and Indonesia [3]. - The company has filed a biologics license application (BLA) seeking full approval for its vaccine, with a decision from the FDA anticipated earlier this month [3][4]. - The delay in the FDA's decision is speculated to be linked to the resignation of Dr. Peter Marks, a key FDA official, who cited irreconcilable differences with the new HHS Secretary [4][9]. - Year-to-date, Novavax's shares have decreased by 32.5%, contrasting with the industry's decline of 7.9% [5]. Industry Summary - The concerns expressed by the HHS Secretary have also negatively impacted other vaccine manufacturers, with Pfizer's shares down by 3.9% and Moderna's shares down by 8.1% following the news [6]. - The market is reacting to the potential implications of Dr. Marks' resignation, which may weaken the FDA's role in ensuring timely access to safe and effective therapies, thereby adding challenges to the biotech sector [10].

President Trump's trade policies are sending many stocks that were performing well in the wrong direction and exacerbating things for others that were already struggling. So, the time seems ripe for investors to look for bargains.However, not every beaten-down stock is worth investing in -- many look more like value traps than anything else, no matter how low their share prices have fallen. Consider two examples: Tilray (TLRY -2.65%) and Novavax (NVAX 4.81%). Both companies are trading well below $10 due to ...

Group 1: Novavax Stock Performance - Novavax (NVAX) shares increased by 11.4% to close at $6.24, following a significant trading volume compared to normal sessions, despite a 28.8% loss over the past four weeks [1][2] - The stock price recovery is attributed to a rebound after an 8-session decline, with investors optimistic about a favorable FDA decision regarding the company's protein-based COVID-19 vaccine [2] Group 2: Financial Expectations - Novavax is projected to report a quarterly loss of $0.43 per share, reflecting a year-over-year increase of 59.1%, while revenues are expected to be $72.27 million, down 23% from the previous year [3] - The consensus EPS estimate for Novavax has been revised 7.6% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Group 3: Industry Context - Novavax operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Travere Therapeutics (TVTX), experienced a 9.5% decline to $14.99, with a -12.6% return over the past month [4] - Travere's consensus EPS estimate remains unchanged at -$0.54, representing a year-over-year change of 69.3% [5]

Novavax (NVAX) closed at $7.26 in the latest trading session, marking a -1.76% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.33% for the day. Meanwhile, the Dow lost 0.37%, and the Nasdaq, a tech-heavy index, lost 0.53%.Prior to today's trading, shares of the vaccine maker had gained 0.96% over the past month. This has outpaced the Medical sector's loss of 3.24% and the S&P 500's loss of 4.03% in that time.The upcoming earnings release of Novavax will be of great ...

Group 1: Tilray Brands - Tilray Brands is a leader in the cannabis market, but the industry has been underperforming in recent years [3] - The legal landscape remains unfavorable, with federal prohibition in the U.S. and challenges in Canada such as stringent licensing, oversupply, and competition from illicit markets [4] - The company's financial results are poor, with revenue growth primarily from acquisitions and ongoing unprofitability [5] - Despite diversifying into the U.S. craft brewing market, Tilray's future relies heavily on the legalization of recreational cannabis in the U.S., which may come with regulatory challenges [6][7] - Historical performance indicates that even with potential legalization, Tilray's prospects remain bleak, making it unattractive for investment [9] Group 2: Novavax - Novavax's shares have significantly declined over the past three years, nearing their 52-week low of $3.81 [10] - Initially a strong contender in the COVID-19 vaccine market, Novavax fell behind competitors like Moderna and Pfizer/BioNTech [11] - A deal with Sanofi provided Novavax with $500 million upfront and potential milestone payments, temporarily boosting its stock [12] - Despite this, Novavax must still develop and market its own products, facing regulatory setbacks that highlight its high-risk nature [14] - The crowded flu vaccine market poses additional challenges, with mRNA candidates likely to dominate, making Novavax's offerings less attractive [15][16]

Core Insights - Dr. Young will resign from Novavax's board effective March 10, 2025, after serving since 2010 and as Chair since 2011, during which he guided significant acquisitions and the commercialization of the COVID-19 vaccine [1] - The company is transitioning leadership to Margie McGlynn, who has extensive experience in the vaccine sector, and John C. Jacobs, the current CEO, emphasizing a strong foundation for future growth [2] - Novavax's growth strategy focuses on building diversified partnerships and out-licensing its technology platform and vaccine assets, aiming to expand its early-stage pipeline [4] Leadership Transition - Dr. Young's leadership was pivotal in establishing Novavax's strategic direction, including partnerships and the development of its technology platform [1][2] - Margie McGlynn, with a background in vaccine development and leadership roles, is expected to drive the company's corporate growth strategy [2][3] - The board's collective experience is seen as a strength for advancing Novavax's objectives [2] Company Strategy - Novavax aims to tackle significant health challenges through its innovative vaccine technology, including the Matrix-M™ adjuvant [4] - The company is focusing on strategic collaborations to enhance its research and development capabilities and expand into new disease areas [4] - Investments in an early-stage pipeline are central to Novavax's strategy, leveraging its expertise in infectious diseases [4]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Viking Therapeutics (VKTX 3.06%) and Novavax (NVAX -3.55%) were two of the big winners in the biotech industry last year. Both companies saw their shares rise significantly; the former had exciting clinical progress, while the latter signed a lucrative deal with a biotech giant that had Wall Street cheering.Are these stocks worth buying in 2025 after their strong performance last year? My view is that only one of them looks attractive, while the other isn't worth the trouble. Here's why.The biotech stock to ...

Group 1 - Novavax, Inc. will participate in several upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference and the Leerink Partners 2025 Global Healthcare Conference [1][2] - The TD Cowen conference will feature a fireside chat on March 4, 2025, while the Leerink Partners conference will include a presentation on the same date [1] - A webcast of the events will be available on the company's website, with replays accessible for 30 days post-conference [2] Group 2 - Novavax focuses on addressing significant health challenges through its expertise in vaccines and advanced technology platforms, including a protein-based nanoparticle and Matrix-M™ adjuvant [3] - The company's growth strategy emphasizes forming new partnerships by out-licensing its technology and vaccine assets early in the development process [3] - Novavax aims to expand its early-stage pipeline, starting with infectious diseases and potentially branching into other areas [3]

Novavax (NVAX) incurred a fourth-quarter 2024 loss of 51 cents per share, narrower than the Zacks Consensus Estimate of a loss of 75 cents. In the year-ago quarter, the company reported a loss of $1.44 per share.Revenues in the quarter amounted to $88.3 million, which beat the Zacks Consensus Estimate of $86 million. However, the top line declined 70% on a year-over-year basis.See the Zacks Earnings Calendar to stay ahead of market-making news.Year to date, Novavax stock has declined 9% against the industry ...